

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:

NEW ASSIGNMENT

NATURE OF CONVEYANCE:

SECURITY AGREEMENT

CONVEYING PARTY DATA

Name	Execution Date
TALECRIS BIOTHERAPEUTICS HOLDINGS CORP.	12/06/2006
TALECRIS BIOTHERAPEUTICS, INC.	12/06/2006
PRECISION PHARMA SERVICES, INC.	12/06/2006
TALECRIS PLASMA RESOURCES, INC.	12/06/2006

RECEIVING PARTY DATA

Name:	WELLS FARGO FOOTHILL, INC., AS COLLATERAL AGENT
Street Address:	2450 Colorado Ave.
Internal Address:	Suite 3000 West
City:	Santa Monica
State/Country:	CALIFORNIA
Postal Code:	90404

Name:	Wachovia Bank, National Association, as Administrative Agent
Street Address:	1133 Avenue of the America
City:	New York
State/Country:	NEW YORK
Postal Code:	10036

PROPERTY NUMBERS Total: 40

Property Type	Number
Patent Number:	5985836
Patent Number:	5723579
Patent Number:	5356878
Patent Number:	5177191
Patent Number:	4659563
Patent Number:	4717766

PATENT

500244314

REEL: 019047 FRAME: 0296

OP \$1600.00 5985836

Patent Number:	4801450
Patent Number:	4665159
Patent Number:	4717564
Patent Number:	5561115
Patent Number:	5844087
Patent Number:	6121422
Patent Number:	5911165
Patent Number:	5248596
Patent Number:	4656254
Patent Number:	6462180
Patent Number:	4697003
Patent Number:	4684723
Patent Number:	6355243
Patent Number:	6969515
Patent Number:	6964764
Patent Number:	6391298
Patent Number:	6521226
Patent Number:	6984492
Patent Number:	5783663
Patent Number:	5688912
Patent Number:	5831003
Patent Number:	5561108
Patent Number:	RE36259
Patent Number:	5250663
Patent Number:	5610285
Application Number:	09689505
Application Number:	11367772
Application Number:	10692105
Application Number:	10143156
Application Number:	11568023
Application Number:	10143112
Application Number:	60763422
Application Number:	11470390
Application Number:	60820704

CORRESPONDENCE DATA

Fax Number: (312)701-7711

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 312-701-7237

Email: cdore@mayerbrownrowe.com

Correspondent Name: Christopher Dore

Address Line 1: 71 S. Wacker Drive

Address Line 2: Mayer Brown Rowe & Maw LLP

Address Line 4: Chicago, ILLINOIS 60606-4637

NAME OF SUBMITTER:

Christopher Dore

Total Attachments: 18

source=PAT SI Foothill#page1.tif
source=PAT SI Foothill#page2.tif
source=PAT SI Foothill#page3.tif
source=PAT SI Foothill#page4.tif
source=PAT SI Foothill#page5.tif
source=PAT SI Foothill#page6.tif
source=PAT SI Foothill#page7.tif
source=PAT SI Foothill#page8.tif
source=PAT SI Foothill#page9.tif
source=PAT SI Foothill#page10.tif
source=PAT SI Foothill#page11.tif
source=PAT SI Foothill#page12.tif
source=PAT SI Foothill#page13.tif
source=PAT SI Foothill#page14.tif
source=PAT SI Foothill#page15.tif
source=PAT SI Foothill#page16.tif
source=PAT SI Foothill#page17.tif
source=PAT SI Foothill#page18.tif

THE EXERCISE BY THE ADMINISTRATIVE AGENT OR ANY OTHER SECURED PARTY OF THEIR RIGHTS HEREUNDER IS SUBJECT TO THE TERMS, CONDITIONS AND RESTRICTIONS OF THE INTERCREDITOR AGREEMENT REFERRED TO IN SECTION 5 OF THIS AGREEMENT.

PATENT SECURITY AGREEMENT

This PATENT SECURITY AGREEMENT (this "Agreement"), dated as of December 6, 2006 between each of the undersigned (each, a "Grantor"), Wells Fargo Foothill, Inc., acting in the capacity of agent for itself and the Secured Parties (in such capacity, the "Collateral Agent") and Wachovia Bank, National Association, acting in the capacity of agent for itself and the Secured Parties (in such capacity, the "Administrative Agent").

WITNESSETH:

WHEREAS pursuant to the terms of that certain Revolving Credit Agreement, dated as of December 6, 2006 (as it may be amended, restated, supplemented or otherwise modified from time to time, the "Credit Agreement"), by and among Talecris Biotherapeutics Holdings Corp., Talecris Biotherapeutics, Inc., Precision Pharma Services, Inc., Talecris Plasma Resources, Inc. (each, and each other Person that becomes a party to the Credit Agreement as a Borrower, individually, a "Borrower" and, collectively, the "Borrowers"), the Lenders party thereto from time to time, the Collateral Agent and the Administrative Agent, such Lenders have agreed to extend credit and make certain financial accommodations to the Borrowers;

WHEREAS pursuant to the Pledge and Security Agreement, dated as of December 6, 2006 (as it may be amended, restated, supplemented or otherwise modified from time to time, the "Security Agreement"), between the Grantors and the Administrative Agent, each Grantor granted to the Administrative Agent a security interest and continuing lien on all of such Grantor's right, title and interest in, to and under all Collateral (as defined in the Security Agreement), including the Patent Collateral (as defined below), and all Collateral, in each case whether now owned or existing or hereafter acquired or arising and wherever located, to secure the prompt and complete payment and performance of all Secured Obligations (as defined in the Security Agreement), including the obligations of the Borrowers under the Credit Agreement;

WHEREAS pursuant to the Credit Agreement and pursuant to Section 5.1(a) of the Security Agreement, the Grantors are required to execute and deliver this Agreement and to grant to the Administrative Agent a continuing security interest in all of the Patent Collateral (as defined below) to secure all Obligations; and

NOW, THEREFORE, in consideration of the premises and the agreements, provisions and covenants herein contained, each Grantor agrees as follows:

Section 1. Defined Terms

Unless otherwise defined herein, capitalized terms defined in the Security Agreement and used herein have the meaning given to them in the Security Agreement.

Section 2. Grant of Security Interest in Patents

Each Grantor hereby grants to the Administrative Agent a security interest and continuing lien on all of such Grantor's right, title and interest in, to and under the Patents, including the Patents listed in Schedule I, in each case whether owned or existing or hereafter acquired or arising and wherever located (collectively, the "Patent Collateral").

Section 3. Security for Obligations

This Agreement secures, and the Patent Collateral is collateral security for, the prompt and complete payment and performance in full when due, whether at stated maturity, by required prepayment, declaration, acceleration, demand or otherwise (including the payment of amounts that would become due but for the operation of the automatic stay under Section 362(a) of the Bankruptcy Code, 11 U.S.C. §362(a) (and any successor provision thereof)), of all Secured Obligations.

Section 4. Security Agreement

The security interests granted pursuant to this Agreement are granted in conjunction with the security interests granted to the Administrative Agent pursuant to the Security Agreement and each Grantor hereby acknowledges and affirms that the rights and remedies of the Administrative Agent with respect to the security interest in the Patent Collateral made and granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. In the event of any irreconcilable conflict between the terms of this Agreement and the terms of the Security Agreement, the terms of the Security Agreement shall control.

Section 5. Intercreditor Agreement

Notwithstanding anything herein to the contrary, the lien and security interest granted to the Administrative Agent pursuant to this Agreement and the exercise of any right or remedy by the Administrative Agent hereunder is subject to the terms, conditions and provisions of the Intercreditor Agreement in all respects. In the event of any conflict between the terms of the Intercreditor Agreement and this Agreement, the terms of the Intercreditor Agreement shall govern and control in all respects.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, each Grantor has caused this Agreement to be duly executed and delivered by its duly authorized officer as of the date first set forth above.

Very truly yours,

TALECRIS BIOTHERAPEUTICS HOLDINGS
CORP.,

as Grantor

By: 

Name: John Hanson

Title: Exec VP & CFO, Treasurer

TALECRIS BIOTHERAPEUTICS, INC.

as Grantor

By: 

Name: John Hanson

Title: Exec VP & CFO

PRECISION PHARMA SERVICES, INC.

as Grantor

By: 

Name: John Hanson

Title: Exec. VP & CFO

TALECRIS PLASMA RESOURCES, INC.

as Grantor

By: 

Name: John Hanson

Title: Exec VP & CFO

ACCEPTED AND AGREED
as of the date first above written:

WACHOVIA BANK, NATIONAL ASSOCIATION,
as Administrative Agent

By: Thomas Grabosky
Name: Thomas Grabosky
Title: Director

WELLS FARGO FOOTHILL, INC.,
As Collateral Agent


By: _____
Name:
Title:

ACCEPTED AND AGREED
as of the date first above written:

WACHOVIA BANK, NATIONAL ASSOCIATION,
as Administrative Agent

By: _____
Name:
Title:

WELLS FARGO FOOTHILL, INC.,
As Collateral Agent

By:  _____
Name: *Nan Wong*
Title: *Vice-President*

Patent Security Agreement - Revolver (Wells Fargo)

PATENT
REEL: 019047 FRAME: 0303

SCHEDULE I
TO
PATENT SECURITY AGREEMENT

Title	Country	Serial No.	Filing Date	Patent No.	Issue Date
Alpha-1 Proteinase Inhibitor Binding Peptides	US	09/127,574	07/31/98	5,985,836	11/13/99
Covalently Attached Complex of Alpha-I Proteinase Inhibitor with a Water Soluble Polymer	CA	465464	10/15/84	1242664	10/04/88
Covalently Bound Heparin-Antithrombin-III Complex	CA	463807	09/21/84	1240264	08/09/88
Diagnostic Probes for Detecting Elastase Modified Antithrombin and Methods of Treatment	CA	559,743	02/24/88	1,320,682	07/27/93
Diagnostic Probes for Detecting Elastase Modified Antithrombin and Methods of Treatment	JP	39765/88	02/24/88	2,549,138	08/08/96
Fibrinogen Binding Peptides	AU	12355/97	01/28/97	710041	12/23/99
Fibrinogen Binding Peptides	CA	2,196,368	01/30/97		
Fibrinogen Binding Peptides	CA	2,196,368	01/30/97		
Fibrinogen Binding Peptides	JP	29838/97	01/30/97		
Fibrinogen Binding Peptides	US	08/595,718	02/02/96	5,723,579	03/03/98
Gel Filtration of Factor VII	AU	17310/88	12/20/88	626275	11/24/92
Gel Filtration of Factor VIII	CA	586473	12/20/88	1339477	09/23/97

Title	Country	Serial No.	Filing Date	Patent No.	Issue Date
Gel Filtration of Factor VIII	EP* *Licensed to Sclavo for use in Italy, Vatican City, and San Marino	88120808.6	12/13/88	0321836	09/28/94
Gel Filtration of Factor VIII	JP	316557/88	12/16/88	6289390	08/29/97
Gel Filtration of Factor VIII	US	852 DIV' 815	01/04/93	5,356,878	10/18/94
Gel Filtration of Factor VIII	US	587815 CON' 966	09/24/90	5,177,191	01/05/93
High Titer Anti-Respiratory Syncytial Virus Intravenous Immune Globulin	CA	528,196	01/26/87	1,313,820	02/23/93
High Titer Anti-Respiratory Syncytial Virus Intravenous Immune Globulin	IT	19086A/87	01/14/87	1,201,153	01/27/89
High Titer Anti-Respiratory Syncytial Virus Intravenous Immune Globulin	JP	14324/87	01/26/87	2,659,093	06/06/97
High Titer Anti-Respiratory Syncytial Virus Intravenous Immune Globulin	US	06/822,560	01/27/86	4,659,563	04/21/87
High Titer Anti-Respiratory Syncytial Virus Intravenous Immune Globulin	US	07/023,339	03/09/87	4,717,766	01/05/88
High Titer Cytomegalovirus Immune Serum Globulin	CA	456425	06/13/84	1244767	11/15/88
High Titer Pseudomonas Immune Serum Globulin	CA	456,424	06/13/84	1,247,527	12/28/88
High Titer Pseudomonas Immune Serum Globulin	US	859,944	05/05/86	4,801,450	01/31/89
High Titer Varicella-Zoster Immune Globulin for Intravenous Administration	CA	522,253	11/05/86	1,321,143	08/10/93
High Titer Varicella-Zoster Immune Globulin for Intravenous Administration	US	06/795,811	11/07/85	4,665,159	05/12/87

Title	Country	Serial No.	Filing Date	Patent No.	Issue Date
High Titer Varicella-Zoster Immune Globulin for Intravenous Administration	US	07/023,734	303/09/87	4,717,564	01/05/88
Low Temperature Albumin Fractionation Using Sodium Caprylate as a Partitioning Agent	AU	28390/95	08/03/95	684,202	03/26/98
Low Temperature Albumin Fractionation Using Sodium Caprylate as a Partitioning Agent	CA	2,155,630	08/08/95		
Low Temperature Albumin Fractionation Using Sodium Caprylate as a Partitioning Agent	CN	95109051.8	08/09/95	ZL95109051.9	05/19/04
Low Temperature Albumin Fractionation Using Sodium Caprylate as a Partitioning Agent	EP	95112,061.7	08/01/95	696,595	10/28/98
Low Temperature Albumin Fractionation Using Sodium Caprylate as a Partitioning Agent	JP	218235/95	08/04/95		
Low Temperature Albumin Fractionation Using Sodium Caprylate as a Partitioning Agent	KR	95-24363	08/08/95	418821	02/03/04
Low Temperature Albumin Fractionation Using Sodium Caprylate as a Partitioning Agent	US	08/288,180	08/10/94	5,561,115	10/01/96
Method and Device for Delivering Fibrin Glue	AU	43,644/97	10/30/97	716623	08/03/00
Method and Device for Delivering Fibrin Glue	CA	2,220,184	11/04/97		
Method and Device for Delivering Fibrin Glue	EP	97118781.0	10/29/97	839,498	03/31/04
Method and Device for Delivering Fibrin Glue	JP	312,863/97	10/30/97		
Method and Device for Delivering Fibrin Glue	US	08/744,488	11/05/96	5,844,087	12/01/98
Method and Device for Delivering Fibrin Glue	US	09/200,636	11/25/98	6,121,422	09/19/00

Title	Country	Serial No.	Filing Date	Patent No.	Issue Date
Method and Device for Mechanical Testing of Fibrin Glue Strength	US	08/864,797	05/29/97	5,911,165	06/08/99
Method and System for Allocation of Limited Supply Medication	US	09/689,505	10/13/00		
Method of Detecting Proteolytically Modified Antithrombin	US	07/844,354	03/02/92	5,248,596	09/28/93
Method of Preparing Alpha-1 - Proteinase Inhibitor and Antithrombin III	US	803184	12/02/85	4,656,254	04/07/87
Method of Preparing Alpha-1 Proteinase Inhibitor	AU	45240/01	12/14/00		
Method of Preparing Alpha-1 Proteinase Inhibitor	CA	521806	10/30/86	1286848	07/23/91
Method of Preparing Alpha-1 Proteinase Inhibitor	CA	2,432,641	12/14/00		
Method of Preparing Alpha-1 Proteinase Inhibitor	EP	00992709	12/14/00		
Method of Preparing Alpha-1 Proteinase Inhibitor	NO	2003 2700	12/14/00		
Method of Preparing Alpha-1 Proteinase Inhibitor	NZ	526940	12/14/00		
Method of Preparing Alpha-1 Proteinase Inhibitor	US	PCT/US00/42811	12/14/00		
Method of Preparing Alpha-1 Proteinase Inhibitor	US	09/449,695	11/24/99	6,462,180	10/08/02
Method of Preparing Alpha-1 Proteinase Inhibitor	US	793807	11/01/85	4,697,003	09/29/87
Method of Preparing Alpha-1 Proteinase Inhibitor and Antithrombin	AU	65888/86	12/02/86	591734	04/12/90
Method of Preparing Alpha-1 Proteinase Inhibitor and Antithrombin	EP	86116125.5	11/21/86	0224811	08/19/92
Method of Preparing Alpha-1 Proteinase Inhibitor and Antithrombin	JP	284445/86	12/01/86	2030723	03/19/96

Title	Country	Serial No.	Filing Date	Patent No.	Issue Date
Method of Preparing Alpha-I - Proteinase Inhibitor and Antithrombin III	CA	524266	12/01/86	1298032	03/24/92
Method of Preparing Highly Purified Alpha-1 Proteinase Inhibitor	CA	565058	04/26/88	1,340,236	12/15/98
Method of Preparing Highly Purified Alpha-1 Proteinase Inhibitor	EP	88/106017	04/15/88	288,841	12/30/92
Method of Separating Proteins from Aqueous Solutions	US	06/774,677	09/11/85	4,684,723	08/04/87
Method of Thrombolysis by Local Delivery of Active Plasmin, Plasmin Formulation and Process of Producing	US	09/438,331	11/13/99	6,355,243	03/12/02
Method of Thrombolysis by Local Delivery of Reversibly Acidified Plasmin	AU	16025/01	11/13/00		
Method of Thrombolysis by Local Delivery of Reversibly Acidified Plasmin	US	10/280,444	10/25/02	6969515	11/29/05
Method of Thrombolysis by Local Delivery of Reversibly Inactivated Acidified Plasmin	AU	200116025	11/13/00	784598	05/11/06
Method of Thrombolysis by Local Delivery of Reversibly Inactivated Acidified Plasmin	CA	2,389,345	11/13/00		
Method of Thrombolysis by Local Delivery of Reversibly Inactivated Acidified Plasmin	EP	0978572	11/13/00		
Method of Thrombolysis by Local Delivery of Reversibly Inactivated Acidified Plasmin	JP	538488/01	11/13/00		
Method of Thrombolysis by Local Delivery of Reversibly Inactivated Acidified Plasmin	US	10/143,157	05/10/02	6964764	11/15/05
Method of Thrombolysis by Local Delivery of Reversibly Inactivated Acidified Plasmin	WO	PCT/US00/31115	11/13/00		

Title	Country	Serial No.	Filing Date	Patent No.	Issue Date
Method of Using PON-1 to Decrease Atheroma Formation	AU	23471/01	11/23/99	773134	05/20/04
Method of Using PON-1 to Decrease Atheroma Formation	CA	2,350,405	11/23/99		
Method of Using PON-1 to Decrease Atheroma Formation	EP	99967126	11/23/99	1 131 909 B1	11/16/05
Method of Using PON-1 to Decrease Atheroma Formation	JP	583326/00	11/23/99		
Method of Using PON-1 to Decrease Atheroma Formation	US	09/199,672	11/25/98	6,391,298	05/21/02
Method of Using PON-1 to Decrease Atheroma Formation	US	10/105,640	03/25/02	6,521,226	02/18/03
Method of Using PON-1 to Decrease Atheroma Formation	WO	PCT/US99/27806	11/23/99	Pub. No. 00/30425 A2	Pub. Date 6/2/2000
Methods and Compositions for Treating Herpes Infections	AU	2004272001	04/02/04		
Methods and Compositions for Treating Herpes Infections	BR				
Methods and Compositions for Treating Herpes Infections	CA	2537360	09/02/04		
Methods and Compositions for Treating Herpes Infections	CN	80025305	09/01/04		
Methods and Compositions for Treating Herpes Infections	EP	2004782951	09/02/04		
Methods and Compositions for Treating Herpes Infections	IL				
Methods and Compositions for Treating Herpes Infections	JP				
Methods and Compositions for Treating Herpes Infections	KR				
Methods and Compositions for Treating Herpes Infections	MX				

Title	Country	Serial No.	Filing Date	Patent No.	Issue Date
Methods and Compositions for Treating Herpes Infections	NO	20061184	03/14/06		
Methods and Compositions for Treating Herpes Infections	NZ				
Methods and Compositions for Treating Herpes Infections	ZA				
Methods and Compositions for Treating Herpes Infections	PCT	US04/028559	09/02/04		
Methods and Compositions for Treating Herpes Infections	US	11/367772	03/03/06		
Methods and Compositions for Treating Herpes Infections	US	10/656781	09/05/03	6984492	01/10/06
Methods and Compositions for Treating Herpes Infections	WO	PCT/US04/28559	09/01/04		
Peptide Ligands for Affinity Purification of Fibrinogen	JP	216,537/98	07/16/98		
Peptide Ligands for Affinity Purification of Fibrinogen	US	09/012,343	01/23/98	5,783,663	07/21/98
Peptide Ligands Which Bind to Von Willebrand Factor	AU	65689/96	09/18/96	706,019	09/16/99
Peptide Ligands Which Bind to Von Willebrand Factor	CA	2,185,856	09/18/96		
Peptide Ligands Which Bind to Von Willebrand Factor	JP	266,798/96	09/17/96		
Peptide Ligands Which Bind to Von Willebrand Factor	US	08/537,069	09/22/95	5,688,912	11/18/97
Peptides Which Bind to Prothrombin and Thrombin	AU	26220/97	06/23/97	712575	02/24/00
Peptides Which Bind to Prothrombin and Thrombin	CA	2,206,663	06/25/97		
Peptides Which Bind to Prothrombin and Thrombin	EP	97/109744	06/16/97	816377	04/10/02

Title	Country	Serial No.	Filing Date	Patent No.	Issue Date
Peptides Which Bind to Prothrombin and Thrombin	JP	181895/97	06/24/97		
Peptides Which Bind to Prothrombin and Thrombin	US	08/672,805	06/28/96	5,831,003	11/03/98
Preparation of Alpha-1 Antichymotrypsin	AU	27143/95	07/24/95	700,921	04/24/99
Preparation of Alpha-1 Antichymotrypsin	CA	2,154,982	07/28/95		
Preparation of Alpha-1 Antichymotrypsin	CN	95115233.5	07/28/95	ZL95115233.5	11/10/04
Preparation of Alpha-1 Antichymotrypsin	EP	95111304.2	07/19/95	0694562	11/08/00
Preparation of Alpha-1 Antichymotrypsin	JP	209,351/95	07/26/95		
Preparation of Alpha-1 Antichymotrypsin	KR	95-22667	07/28/95	433115	05/17/04
Preparation of Alpha-1 Antichymotrypsin	US	08/282,860	07/29/94	5,561,108	10/01/96
Preparing Essentially Monomeric Normal Human Serum Albumin	EP	91105453.4	04/06/91	0452753	06/23/04
Preparing Essentially Monomeric Normal Human Serum Albumin	US	276861 RE' 439	07/18/94	RE36259	07/27/99
Preparing Essentially Monomeric Normal Human Serum Albumin	US	848439 DIV' 362	03/09/92	5,250,663	10/05/93
Process for Producing High Purity Antihemophilic Factor Concentrate	CA	486,007	06/28/85	1,243,950	11/01/88
Process for the Production of a Reversibly Inactive Acidified Plasmin Composition	AU	200136436	11/13/00	784800	06/22/06
Process for the Production of a Reversibly Inactive Acidified Plasmin Composition	CA	2,389,487	11/13/00		

Title	Country	Serial No.	Filing Date	Patent No.	Issue Date
Process for the Production of a Reversibly Inactive Acidified Plasmin Composition	EP	00991956	11/13/00		
Process for the Production of a Reversibly Inactive Acidified Plasmin	JP	538490/01	11/13/00		
Process for the Production of a Reversibly Inactive Acidified Plasmin	US	10/692,105	10/23/03	Pub. No. 2004/ 0171103	
Process for the Production of a Reversibly Inactive Acidified Plasmin Composition	US	10/143,156	05/10/02	Pub. No. 2002/ 0192794	
Process for the Production of a Reversibly Inactive Acidified Plasmin	WO	PCT/US00/42143	11/13/00		
Purification of Alpha-1 Proteinase Inhibitor Using Novel Chromatographic Separation Conditions	AT	95112630.9	08/11/95	0698615	12/08/99
Purification of Alpha-1 Proteinase Inhibitor Using Novel Chromatographic Separation Conditions	AU	30111/95	08/17/95	700638	04/22/99
Purification of Alpha-1 Proteinase Inhibitor Using Novel Chromatographic Separation Conditions	BE	95112630.9	08/11/95	0698615	12/08/99
Purification of Alpha-1 Proteinase Inhibitor Using Novel Chromatographic Separation Conditions	CA	2,156,007	08/14/95		
Purification of Alpha-1 Proteinase Inhibitor Using Novel Chromatographic Separation Conditions	CH	95112630.9	08/11/95	698615	12/08/99
Purification of Alpha-1 Proteinase Inhibitor Using Novel Chromatographic Separation Conditions	CN	95108778.9	08/23/95	ZL95108778. 9	08/11/04

Title	Country	Serial No.	Filing Date	Patent No.	Issue Date
Purification of Alpha-1 Proteinase Inhibitor Using Novel Chromatographic Separation Conditions	CN	0410069444.7	08/23/95		
Purification of Alpha-1 Proteinase Inhibitor Using Novel Chromatographic Separation Conditions	DE	95112630.9	08/11/95	698615	12/08/99
Purification of Alpha-1 Proteinase Inhibitor Using Novel Chromatographic Separation Conditions	DK	95112630.9	08/11/95	0698615	12/08/99
Purification of Alpha-1 Proteinase Inhibitor Using Novel Chromatographic Separation Conditions	EP	95112630.9	08/11/95	698615	12/08/99
Purification of Alpha-1 Proteinase Inhibitor Using Novel Chromatographic Separation Conditions	ES	95112630.9	08/11/95	698615	12/08/99
Purification of Alpha-1 Proteinase Inhibitor Using Novel Chromatographic Separation Conditions	FR	95112630.9	08/11/95	698615	12/08/99
Purification of Alpha-1 Proteinase Inhibitor Using Novel Chromatographic Separation Conditions	GR	95112630.9	08/11/95	698615	12/08/99
Purification of Alpha-1 Proteinase Inhibitor Using Novel Chromatographic Separation Conditions	IE	95112630.9	08/11/95	698615	12/08/99
Purification of Alpha-1 Proteinase Inhibitor Using Novel Chromatographic Separation Conditions	IT	95112630.9	08/11/95	698615	12/08/99
Purification of Alpha-1 Proteinase Inhibitor Using Novel Chromatographic Separation Conditions	JP	233,228/95	08/21/95		

Title	Country	Serial No.	Filing Date	Patent No.	Issue Date
Purification of Alpha-1 Proteinase Inhibitor Using Novel Chromatographic Separation Conditions	KR	95-26050	08/23/95	451266	09/20/04
Purification of Alpha-1 Proteinase Inhibitor Using Novel Chromatographic Separation Conditions	LU	95112630.9	08/11/95	698615	12/08/99
Purification of Alpha-1 Proteinase Inhibitor Using Novel Chromatographic Separation Conditions	MC	95112630.9	08/11/95	698615	12/08/99
Purification of Alpha-1 Proteinase Inhibitor Using Novel Chromatographic Separation Conditions	NL	95112630.9	08/11/95	698615	12/08/99
Purification of Alpha-1 Proteinase Inhibitor Using Novel Chromatographic Separation Conditions	PT	95112630.9	08/11/95	698615	12/08/99
Purification of Alpha-1 Proteinase Inhibitor Using Novel Chromatographic Separation Conditions	SE	95112630.9	08/11/95	698615	12/08/99
Purification of Alpha-1 Proteinase Inhibitor Using Novel Chromatographic Separation Conditions	UK	95112630.9	08/11/95	698615	12/08/99
Purification of Alpha-1 Proteinase Inhibitor Using Novel Chromatographic Separation Conditions	US	08/295,119	08/24/94	5,610,285	03/11/97
Recombinantly Modified Plasmin	AE				
Recombinantly Modified Plasmin	AU				
Recombinantly Modified Plasmin	BR				
Recombinantly Modified Plasmin	CA				
Recombinantly Modified Plasmin	CN				

Title	Country	Serial No.	Filing Date	Patent No.	Issue Date
Recombinantly Modified Plasmin	DZ				
Recombinantly Modified Plasmin	EA				
Recombinantly Modified Plasmin	EG				
Recombinantly Modified Plasmin	EP				
Recombinantly Modified Plasmin	IN				
Recombinantly Modified Plasmin	ID				
Recombinantly Modified Plasmin	IR				
Recombinantly Modified Plasmin	IL				
Recombinantly Modified Plasmin	JO				
Recombinantly Modified Plasmin	JP				
Recombinantly Modified Plasmin	KR				
Recombinantly Modified Plasmin	LB				
Recombinantly Modified Plasmin	MA				
Recombinantly Modified Plasmin	MX				
Recombinantly Modified Plasmin	NZ				
Recombinantly Modified Plasmin	NO				
Recombinantly Modified Plasmin	SG				
Recombinantly Modified Plasmin	SY				
Recombinantly Modified Plasmin	TN				
Recombinantly Modified Plasmin	ZA				
Recombinantly Modified Plasmin	US	11/568,023	04/22/04		
Recombinantly Modified Plasmin	WO	PCT/US05/13562	04/21/05		
Recombinantly Modified Plasmin (Ophthalmic Methods)	JO				

Title	Country	Serial No.	Filing Date	Patent No.	Issue Date
Recombinantly Modified Plasmin (Ophthalmic Methods)	SA				
Recombinantly Modified Plasmin (Ophthalmic Methods)	TW				
Recombinantly Modified Plasmin (Ophthalmic Methods)	WO	PCT/US2006/40940	10/18/06		
Reversibly Inactivated Acidified Plasmin	AU	30724/01	11/13/00	784534	04/27/06
Reversibly Inactivated Acidified Plasmin	CA	2,389,337	11/13/00		
Reversibly Inactivated Acidified Plasmin	EP	0990910	11/13/00		
Reversibly Inactivated Acidified Plasmin	JP	538487/01	11/13/00		
Reversibly Inactivated Acidified Plasmin	PCT	PCT/US00/31090	11/13/00		
Reversibly Inactivated Acidified Plasmin	US	10/143,112	05/10/02	Pub. No. 2003/ 0012778	
Stabilized Immune Serum Globulin	CA	335,260	09/10/79	1,117,417	02/02/82
Methods of Treatment and Prophylaxis Using IgM	US	60/763,422	01/30/06		
Apparatus and Method for Handling and Opening a Frangible Container	US	11/470,390	09/06/06		
Method for Supplying Pharmaceutical Drugs	US	60/820,704	07/28/06		